AffyImmune Therapeutics Alternatives & Competitors
12 companies similar to AffyImmune Therapeutics — Biotechnology startup developing Tune & Track platform to expand utility & impro...
Flare Therapeutics
Trailblazing the path to drugging transcription factors to discover precision medicines fo...
Cambridge, United States
Qualisure Diagnostics Inc.
Deploying AI-enabled molecular diagnostics globally through decentralized testing and cent...
Calgary, Canada
OncoResponse
Interrogating for Cures
Houston, United States
BlossomHill Therapeutics, Inc.
Addressing urgent unmet medical needs through deeper science, true originality, and rich e...
San Diego, United States
Track all AffyImmune Therapeutics competitors
Get real-time alerts when any of these companies raise funding, hire, or show growth signals.
Deciphera Pharmaceuticals
A member of ONO Group
Waltham, United States
Duke Street Bio
Pioneering Next Generation Cancer Therapies
London, United Kingdom
Freenome
Outpacing cancer starts with early detection
Brisbane, United States
PhotonPharma
An immuno-oncology company unleashing the body to fight cancer
Fort Collins, United Stat...
Immatics
The Global Leader in Precision Targeting of PRAME
Germany
TFC Therapeutics
We are a biotechnology company focused on developing novel biologics to target and elimina...
New York, United States
Immunocore
Science to Transform Lives
Abingdon, United Kingdom
Brenus Pharma
Next-generation cancer treatment bringing the immune system one step ahead of cancer 🧬🟣
Lyon, France
About AffyImmune Therapeutics
Biotechnology startup developing Tune & Track platform to expand utility & improve safety of CAR T therapy for cancer.
Development of CAR T therapies, Affinity tuning of CAR T cells, Noninvasive monitoring technologies, ICAM-1 targeting therapies
Thyroid cancer patients, Patients with anaplastic thyroid cancer, Medical professionals in oncology, Clinical researchers
Clinical-stage, CAR T Cell Therapy, Solid Tumors, Affinity Tuning, AIC100, Refractory Thyroid Cancer, Antigen Targeting, On-target Off-tumor Toxicity, Stomach Cancer, Triple Negative Breast Cancer, Biopharmaceutical, Cell Therapy, Chimeric Antigen Receptor, Cancer Treatment
B2B, B2D
Licensing, Performance Based, Product Sales
Frequently Asked Questions
Don't just read about them. Follow them.
BounceWatch watches AffyImmune Therapeutics and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.
Compiled from the BounceWatch company index. We last looked at AffyImmune Therapeutics on 11 Mar 2026. The 12 companies listed here were last checked between 17 Sep 2025 and 22 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
